Bexson Biomedical is developing an innovative preparation of ketamine to treat chronic and acute pain disorders.
Bexson’s main project is a novel ketamine delivery system, which includes a proprietary formulation enabled by a wearable, minimally invasive, subcutaneous infusion pump with anti-diversion properties.
The company aims to address the limitations of current ketamine formulations to allow dosage control and reduced monitoring.
Bexson raised $4.8 million in a Series A round of financing at the beginning of 2021. Funding will support the company through pre-clinical and GMP manufacturing scale up for its proprietary ketamine formulation, BB106, and the development of a wearable delivery device with leading medical device manufacturer, Stevanato Group.
“Developing New Ketamine Therapies For Large-Market & Orphan Indications”
- Bexson Biomedical Raises $4.8 Million In Oversubscribed Series A (PR Newswire, February 2021)
B2B Pharmaceutical Drug Discovery
Topics of Interest
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates